


# Evaluation of Fever in Infants and Young Children

JENNIFER L. HAMILTON, MD, PhD, FAAFP, *Drexel University College of Medicine, Philadelphia, Pennsylvania*  
SONY P. JOHN, MD, *Chester County Hospital, West Chester, Pennsylvania*

Febrile illness in children younger than 36 months is common and has potentially serious consequences. With the widespread use of immunizations against *Streptococcus pneumoniae* and *Haemophilus influenzae* type b, the epidemiology of bacterial infections causing fever has changed. Although an extensive diagnostic evaluation is still recommended for neonates, lumbar puncture and chest radiography are no longer recommended for older children with fever but no other indications. With an increase in the incidence of urinary tract infections in children, urine testing is important in those with unexplained fever. Signs of a serious bacterial infection include cyanosis, poor peripheral circulation, petechial rash, and inconsolability. Parental and physician concern have also been validated as indications of serious illness. Rapid testing for influenza and other viruses may help reduce the need for more invasive studies. Hospitalization and antibiotics are encouraged for infants and young children who are thought to have a serious bacterial infection. Suggested empiric antibiotics include ampicillin and gentamicin for neonates; ceftriaxone and cefotaxime for young infants; and cefixime, amoxicillin, or azithromycin for older infants. (*Am Fam Physician*. 2013;87(4):254-260. Copyright © 2013 American Academy of Family Physicians.)



**T**he evaluation of febrile children younger than 36 months has long presented the challenge for physicians of ensuring that children with serious bacterial infection are appropriately identified and treated, while minimizing the risks associated with invasive testing, hospitalization, and antibiotic treatment. The epidemiology of febrile illness in children has changed dramatically with the introduction of several vaccines targeted at this age group, and with the use of antibiotic prophylaxis during childbirth. Because of this, earlier guidelines have been questioned.<sup>1-3</sup> This article focuses on previously healthy febrile children younger than 36 months. Those with significant preexisting conditions (e.g., prematurity, immune compromise) should be evaluated on a case-by-case basis.

## Epidemiology

Studies of infants and young children presenting with fever have documented a

dramatic reduction in the incidence of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) infections following the widespread use of immunizations against these organisms. Rates of invasive Hib infection, including meningitis, in children five years and younger have fallen by more than 99 percent since the 1990s.<sup>4</sup> Invasive pneumococcal infection in children declined by 77 percent from 1998 to 2005,<sup>5</sup> and is expected to decline further with the use of the pneumococcal 13-valent conjugate vaccine (Prevnar 13).<sup>5</sup> Rates of invasive Hib and *S. pneumoniae* infections have also decreased in non- or partially vaccinated children,<sup>6</sup> perhaps because of herd immunity.

Urinary tract infections (UTIs) are the most common source of serious bacterial infection in children younger than three months, commonly from *Escherichia coli* or *Klebsiella* species.<sup>7-11</sup> A case series found that pneumonia is the most common serious bacterial infection in children three

to 36 months of age, followed by UTI.<sup>12</sup> A large study found that the rate of hospitalization for UTI, including pyelonephritis and urosepsis, in children younger than 12 months has notably increased.<sup>13</sup> This increase coincides with an increase in *E. coli* and other infections that are resistant to penicillin and ampicillin.<sup>9,14</sup> The cause for this shift in infection and resistance patterns is not clear.

**Clinically Significant Fever**

A clinically significant fever in children younger than 36 months is a rectal temperature of at least 100.4°F (38°C). Axillary, tympanic, and temporal artery measurements have been shown to be unreliable.<sup>15-18</sup> Neonates whose parents report a clinically significant fever may have a serious bacterial infection, even if they do not have a fever at the time of their initial medical evaluation.<sup>19</sup>

**Age Stratification**

Traditionally, guidelines for the management of fever in children have been based on age groups: neonates (younger than 30 days<sup>2</sup> or 28 days<sup>7,20</sup>); young infants (up to two months<sup>21-23</sup> or three months<sup>1,20,24-26</sup>); and older infants and young children (up to 36 months). The precise boundaries delineating these groups are under review.<sup>27</sup> Evidence supporting the use of particular age ranges, especially in children not vaccinated according to the recommended schedule, is limited.

**History and Physical Examination**

Initial history and physical examination in infants and young children with fever is directed at recognition of serious illness. Children known to be immunocompromised (e.g., those with cancer, asplenia, or human

immunodeficiency virus infection) need more extensive evaluation and treatment. Conversely, findings that suggest a benign cause for fever, such as vaccination in the past 24 hours, are reassuring.<sup>10</sup> Teething is rarely associated with a fever of more than 100.4°F<sup>28</sup>; therefore, teething should not prevent a thorough examination in a young child with a fever.

A meta-analysis of febrile children older than one month has identified red flags associated with a high likelihood of serious infection (*Table 1*).<sup>29</sup> The study identified no findings with a negative likelihood ratio of less than 0.1, which would help distinguish children at low risk of serious infection.

**Laboratory Testing and Imaging**

History and physical examination cannot identify all children with serious bacterial infections; therefore, judicious use of imaging and laboratory testing is valuable.

**URINALYSIS AND URINE CULTURE**

Because UTI is a common cause of serious bacterial infection, urinalysis is a key factor in the evaluation of fever in infancy and early childhood. Although this test is often omitted because of the difficulty with obtaining a specimen, a clinically valid urine sample should be obtained for all children younger than 24 months with unexplained fever.<sup>30</sup> The sample may be obtained by catheterization or suprapubic aspiration. In children with voluntary urine control, a clean catch method (urination into a specimen container after cleaning the area around the urethra) may be used. Cultures of specimens collected in a urine bag may have an 85 percent false-positive rate,<sup>30</sup> and urine dipstick testing has a 12 percent false-negative rate.<sup>31</sup> All specimens should be sent for formal urinalysis and culture. UTI rates vary with patient sex and age. In the first three months of life, UTIs are more common in boys than in girls, and much more common in uncircumcised boys. After three months of age, UTIs are more common in girls.<sup>32</sup>

**BLOOD CELL COUNTS AND BLOOD CULTURE**

White blood cell (WBC) counts and absolute neutrophil counts have been used to identify serious bacterial infection, including occult bacteremia. However, recent studies question their utility after early infancy.<sup>6,12,33,34</sup> Although various suggested cutoff values for these tests have high sensitivity and reasonably high specificity, the rarity of bacteremia

**Table 1. Clinical Red Flags for Serious Infection in Children Older than One Month**

Global assessments	Circulatory/respiratory	Other factors
Parental concerns	Crackles	Decreased skin elasticity
Physician instinct	Cyanosis	Hypotension
<b>Child behavior</b>	Decreased breath sounds	Meningeal irritation
Changes in crying pattern	Poor peripheral circulation	Petechial rash
Drowsiness	Rapid breathing	Seizures
Inconsolability	Shortness of breath	Unconsciousness
Moaning		

NOTE: These red flags are associated with a positive likelihood ratio of greater than 5 for serious infection in this population. Information from reference 29.

## Childhood Fever

in this population leads to a low positive predictive value (PPV). For example, the presence of an absolute neutrophil count of 15,000 per mm<sup>3</sup> ( $15 \times 10^9$  per L) has a PPV of only 11 percent.<sup>6</sup> Blood cell counts have higher utility in neonates than in older children.<sup>8,22</sup> In a study of neonates up to 28 days of age, a WBC count lower than 5,000 per mm<sup>3</sup> ( $5 \times 10^9$  per L) or more than 15,000 per mm<sup>3</sup> ( $15 \times 10^9$  per L) had a PPV of 44 percent for serious bacterial infection, and an absolute neutrophil count of more than 10,000 per mm<sup>3</sup> ( $10 \times 10^9$  per L) had a PPV of 71 percent.<sup>8</sup>

Current guidelines recommend a complete blood count with differential and blood culture for infants three months or younger with fever.<sup>35,36</sup> However, some experts recommend a more selective approach in infants older than 28 days, limiting laboratory testing to those with clinical signs of serious infection.<sup>1,2</sup>

### STOOL TESTING

In neonates and young infants, diarrhea with fever suggests a systemic illness, and therefore stool culture and fecal WBC counts are recommended.<sup>27,36,37</sup> There are few studies that suggest the need for stool testing in the absence of a localizing sign, such as diarrhea.

### INFLAMMATORY MARKERS

The clinical utility of C-reactive protein levels in recognizing serious infection in neonates, infants, and young children is being explored.<sup>7,8,11,38</sup> Initial studies indicate that a C-reactive protein level of 2 mg per dL (19 nmol per L) or greater has better sensitivity, specificity, and predictive value than a WBC count of greater than 15,000 per mm<sup>3</sup> or less than 5,000 per mm<sup>3</sup>.<sup>11</sup> A C-reactive protein cutoff value as high as 50 mg per dL (476.2 nmol per L) is also being investigated.<sup>39</sup>

Elevated levels of procalcitonin, another marker of inflammation and bacterial infection, also appear to have better sensitivity, specificity, and predictive value than WBC counts.<sup>40</sup> The theoretical advantages of procalcitonin testing must be balanced against its higher cost, reduced availability, and delay in the availability of results.<sup>1</sup> Moreover, it is unclear whether procalcitonin test results affect clinical decisions to administer antibiotics or hospitalize febrile children.<sup>41</sup>

### LUMBAR PUNCTURE

The success of infant vaccination for *S. pneumoniae* and Hib has greatly reduced the incidence of meningitis,<sup>4,5</sup> limiting the indications for lumbar puncture. The test is recommended for all febrile neonates,<sup>7,42</sup> and for infants and young children with clinical signs of meningitis,

such as nuchal rigidity, petechiae, or abnormal neurologic findings.<sup>2,42</sup>

Lumbar puncture is not recommended for children older than three months unless neurologic signs are present.<sup>2,42</sup> The indications for lumbar puncture in young infants (one to three months of age) are under examination. Research suggests that the test is not needed for all febrile infants in this age group,<sup>12,42</sup> but there is no consensus on appropriate indications.<sup>2,36,43</sup> Two guidelines suggest that a lumbar puncture may be omitted for well-appearing, previously healthy young infants with no focal signs of infection, a WBC count between 5,000 and 15,000 per mm<sup>3</sup>, and no pyuria or bacteriuria on urinalysis.<sup>35,43</sup>

Although low peripheral WBC counts (less than 5,000 per mm<sup>3</sup>) are more often associated with meningitis than with bacteremia,<sup>44</sup> WBC counts should not be used alone to determine which infants need lumbar puncture. Use of a threshold WBC count of less than 5,000 per mm<sup>3</sup> would miss 2.1 cases of meningitis for each one detected, and a WBC count of more than 15,000 per mm<sup>3</sup> would miss 2.7 cases for each one detected.<sup>45</sup>

### IMAGING

Chest radiography may be performed in all neonates with unexplained fever, although supporting evidence is limited.<sup>46,47</sup> Chest radiography is also recommended for young children older than one month demonstrating respiratory symptoms,<sup>36</sup> and for those with a fever of more than 102.2°F (39°C) and a WBC count of more than 20,000 per mm<sup>3</sup> ( $20 \times 10^9$  per L).<sup>47</sup>


### HERPES SIMPLEX VIRAL TESTING

Although herpes simplex virus infection in neonates is uncommon (25 to 50 cases per 100,000 live births in the United States<sup>48,49</sup>), the prevalence of the infection in febrile neonates is similar to that of bacterial meningitis.<sup>48</sup> Risk factors include invasive monitoring during delivery,<sup>49</sup> seizures, cerebrospinal fluid pleocytosis, and the presence of lesions.<sup>27</sup> Birth by cesarean delivery is somewhat protective against transmission of herpes simplex virus.<sup>49</sup> Detection of herpes simplex virus DNA in cerebrospinal fluid via polymerase chain reaction is diagnostic.<sup>50</sup> Use of high-dose intravenous acyclovir, 60 mg per kg per day in three divided doses, has been shown to improve outcomes.<sup>51</sup>

### RAPID VIRAL TESTING

Rapid testing for influenza and other viruses is becoming increasingly available. Children who test positive for influenza are unlikely to have a coexistent serious bacterial infection,<sup>52,53</sup> although those who test positive

## Management of Fever in Children Younger than 36 Months



**Figure 1.** Algorithm for the management of unexplained fever ( $> 100.4^{\circ}\text{F}$  [ $38^{\circ}\text{C}$ ]) in previously healthy children younger than 36 months. (CBC = complete blood count; WBC = white blood cell.)

Information from references 1, 7 through 9, 11, 12, 22, 34, 35, 38, 42, 43, 45, 47, 52, and 56.

for respiratory syncytial virus may still have a significant risk of UTI.<sup>3,54</sup> Initial studies evaluating the use of rapid viral testing for influenza during epidemics have suggested that patients who test positive for influenza do not need other, more invasive testing. In one case series, 40 percent of children younger than 36 months who presented to an emergency department with fever during times of generalized influenza epidemics (100 cases per 100,000 persons) were positive for influenza using rapid testing.<sup>52</sup> However, a Cochrane review concludes that not enough evidence exists to uniformly recommend rapid

viral testing as part of an algorithmic approach to fever in children younger than 36 months.<sup>55</sup>

### Management Strategies

Figure 1 is an algorithm for the management of unexplained fever in children younger than 36 months.<sup>1,7-9,11,12,22,34,35,38,42,43,45,47,52,56</sup> In those receiving inpatient evaluation, empiric antibiotics are recommended after culture specimens have been obtained. The choice of antibiotic is dependent on local resistance patterns. The most common infectious organisms in

**Table 2. Recommended Empiric Antibiotic Therapy for Febrile Children Younger than 36 Months**

Age/Findings	Therapy
Younger than one month	Ampicillin* (100 to 200 mg per kg per day IV or IM divided every six hours) plus gentamicin† (2.5 mg per kg IV or IM every eight hours, with adjustments based on serum levels) <sup>57</sup> Alternative: ampicillin* (100 to 200 mg per kg per day IV or IM divided every six hours) plus cefotaxime (Claforan; 50 mg per kg IV every eight hours) <sup>27</sup>
Older than one month, urinary findings	Cefotaxime* (50 mg per kg IV every eight hours) Alternative: cefixime‡ (Suprax; 8 mg per kg twice on first day, then 8 mg per kg daily) <sup>30</sup>
One to three months, meningitis not suspected	Ceftriaxone (Rocephin; 50 mg per kg per day IV or IM divided every 12 to 24 hours) <sup>27</sup>
One to three months, meningitis is a concern	Ceftriaxone (100 mg per kg per day IV or IM divided every 12 to 24 hours) <sup>27</sup>
One to three months, <i>Listeria</i> or <i>Enterococcus</i> is a concern	Add ampicillin* (100 to 200 mg per kg per day IV or IM divided every six hours) to other antibiotics <sup>36</sup>
Older than three months, suspected pneumonia	Amoxicillin (80 mg per kg per day divided every eight to 12 hours) Alternative: azithromycin (Zithromax; 10 mg per kg orally on day 1, then 5 mg per kg daily for the next four days) <sup>27</sup>

IM = intramuscularly; IV = intravenously.

\*—Dosage for children older than seven days who weigh more than 2,000 g.

†—Dosage for children older than seven days.

‡—Cefixime therapy in children younger than six months is an off-label use.

Information from references 27, 30, 36, and 57.

#### SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	References
Evaluation of febrile infants younger than 29 days should include complete blood count with differential, lumbar puncture, blood culture, chest radiography, urinalysis, and urine culture. Stool testing should be performed if diarrhea is present.	C	2, 7, 36
Evaluation of febrile young infants (older than 28 days but younger than three months) should include urinalysis and urine culture and complete blood count with differential. Omitting lumbar puncture may be considered in well-appearing, previously healthy young infants with no focal signs of infection, a white blood cell count between 5,000 per mm <sup>3</sup> ( $5 \times 10^9$ per L) and 15,000 per mm <sup>3</sup> ( $15 \times 10^9$ per L), and no pyuria or bacteriuria on urinalysis. Stool testing should be performed if diarrhea is present.	C	2, 22, 35, 36, 43
For febrile children older than three months but younger than 36 months, lumbar puncture is not appropriate unless neurologic signs are present.	C	2, 36
In febrile infants older than 28 days, the need for chest radiography is determined by clinical signs on physical and laboratory examinations.	C	36, 47
Urinalysis and urine culture are recommended as part of the evaluation for all febrile infants 24 months of age or younger with unexplained fever.	C	30

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort.xml>.

neonates include group B streptococcus, *E. coli*, *Listeria*, and *Enterococcus*. Intravenous ampicillin and gentamicin are recommended for these infections in neonates.<sup>36,57</sup> Concerns about *E. coli* resistance to ampicillin have led some to also recommend a third-generation cephalosporin, such as cefotaxime (Claforan).<sup>9,14,36</sup>

For most serious bacterial infections in young infants, parenteral ceftriaxone (Rocephin) is effective, although ampicillin may be added if *Listeria* or *Enterococcus* is suspected.<sup>36</sup> In infants one month and older, cefixime (Suprax) or cefotaxime is recommended for UTI<sup>29</sup>; amoxicillin or azithromycin (Zithromax) may



be used for pneumonia.<sup>36</sup> Table 2 summarizes empiric antibiotic therapy for febrile patients younger than 36 months.<sup>27,30,36,57</sup>

If close follow-up is available and there are no signs of serious illness, outpatient management with oral antibiotics may be considered in infants. In infants older than 28 days of age without signs of serious illness or localizing findings on physical examination or laboratory evaluation, outpatient monitoring with close follow-up may be considered in place of initial empiric treatment.<sup>26,27</sup>

**Data Sources:** A literature search was conducted using Medline/Ovid, Cochrane, Essential Evidence Plus, and Web of Knowledge. Search terms included neonatal fever, childhood fever, bacterial illness children, bacterial infection children, axillary thermometer, temporal thermometer, and thermometer accuracy. We also identified articles in which the pre-Hib, pre-pneumococcal vaccine recommendations were originally published, as well as recent studies and reviews that cite these articles. Search dates: July 2011 and September 2011.

### The Authors

JENNIFER L. HAMILTON, MD, PhD, FAAFP, is clerkship director of the Family Medicine Clerkship and is an assistant professor in the Department of Family, Community, and Preventive Medicine at Drexel University College of Medicine in Philadelphia, Pa.

SONY P. JOHN, MD, is an outpatient clinician at Chester County Hospital in West Chester, Pa., and a clinical instructor in the Department of Family, Community, and Preventive Medicine at Drexel University College of Medicine.

Address correspondence to Jennifer L. Hamilton, MD, PhD, FAAFP, Drexel University College of Medicine, 10 Shurs Ln., Ste. 301, Philadelphia, PA 19127 (e-mail: jhamilto@drexelmed.edu). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

### REFERENCES

1. Jhaveri R, Byington CL, Klein JO, Shapiro ED. Management of the non-toxic-appearing acutely febrile child: a 21st century approach. *J Pediatr*. 2011;159(2):181-185.
2. Chancey RJ, Jhaveri R. Fever without localizing signs in children: a review in the post-Hib and postpneumococcal era. *Minerva Pediatr*. 2009;61(5):489-501.
3. Vega R. Rapid viral testing in the evaluation of the febrile infant and child. *Curr Opin Pediatr*. 2005;17(3):363-367.
4. Centers for Disease Control and Prevention. Progress toward elimination of *Haemophilus influenzae* type b invasive disease among infants and children—United States, 1998-2000. *MMWR Morb Mortal Wkly Rep*. 2002;51(11):234-237.
5. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998-2005. *MMWR Morb Mortal Wkly Rep*. 2008;57(6):144-148.
6. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. *Arch Pediatr Adolesc Med*. 2004;158(7):671-675.
7. Bilavsky E, Ashkenazi-Hoffnung L, Yarden-Bilavsky H, Amir J, Livni G. A

search for the 'Holy Grail' in the evaluation of febrile neonates aged 28 days or less: a prospective study. *Scand J Infect Dis*. 2011;43(4):264-268.

8. Bressan S, Andreola B, Cattelan F, Zangardi T, Perilongo G, Da Dalt L. Predicting severe bacterial infections in well-appearing febrile neonates: laboratory markers accuracy and duration of fever. *Pediatr Infect Dis J*. 2010;29(3):227-232.
9. Watt K, Waddle E, Jhaveri R. Changing epidemiology of serious bacterial infections in febrile infants without localizing signs. *PLoS One*. 2010;5(8):e12448.
10. Wolff M, Bachur R. Serious bacterial infection in recently immunized young febrile infants. *Acad Emerg Med*. 2009;16(12):1284-1289.
11. Bilavsky E, Yarden-Bilavsky H, Ashkenazi S, Amir J. C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. *Acta Paediatr*. 2009;98(11):1776-1780.
12. Rudinsky SL, Carstairs KL, Reardon JM, Simon LV, Riffenburgh RH, Tanen DA. Serious bacterial infections in febrile infants in the post-pneumococcal conjugate vaccine era. *Acad Emerg Med*. 2009;16(7):585-590.
13. Copp HL, Halpern MS, Maldonado Y, Shortliffe LD. Trends in hospitalization for pediatric pyelonephritis: a population based study of California from 1985 to 2006. *J Urol*. 2011;186(3):1028-1034.
14. Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. *Pediatrics*. 2003;111(5 pt 1):964-968.
15. Craig JV, Lancaster GA, Taylor S, Williamson PR, Smyth RL. Infrared ear thermometry compared with rectal thermometry in children: a systematic review. *Lancet*. 2002;360(9333):603-609.
16. Craig JV, Lancaster GA, Williamson PR, Smyth RL. Temperature measured at the axilla compared with rectum in children and young people: systematic review. *BMJ*. 2000;320(7243):1174-1178.
17. Dodd SR, Lancaster GA, Craig JV, Smyth RL, Williamson PR. In a systematic review, infrared ear thermometry for fever diagnosis in children finds poor sensitivity. *J Clin Epidemiol*. 2006;59(4):354-357.
18. Al-Mukhaizeem F, Allen U, Komar L, et al. Comparison of temporal artery, rectal and esophageal core temperatures in children: results of a pilot study. *Paediatr Child Health*. 2004;9(7):461-465.
19. Brown L, Shaw T, Moynihan JA, Denmark TK, Mody A, Wittlake WA. Investigation of afebrile neonates with a history of fever. *CJEM*. 2004;6(5):343-348.
20. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research [published correction appears in *Ann Emerg Med*. 1993;22(9):1490]. *Ann Emerg Med*. 1993;22(7):1198-1210.
21. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. *N Engl J Med*. 1993;329(20):1437-1441.
22. Bilavsky E, Yarden-Bilavsky H, Amir J, Ashkenazi S. Should complete blood count be part of the evaluation of febrile infants aged  $\leq 2$  months? *Acta Paediatr*. 2010;99(9):1380-1384.
23. Dagan R, Sofer S, Phillip M, Shachak E. Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections. *J Pediatr*. 1988;112(3):355-360.
24. Bang A, Chaturvedi P. Yale Observation Scale for prediction of bacteremia in febrile children. *Indian J Pediatr*. 2009;76(6):599-604.
25. Dagan R, Powell KR, Hall CB, Menegus MA. Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. *J Pediatr*. 1985;107(6):855-860.
26. Huppler AR, Eickhoff JC, Wald ER. Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature. *Pediatrics*. 2010;125(2):228-233.
27. Ishimine P. Fever without source in children 0 to 36 months of age. *Pediatr Clin North Am*. 2006;53(2):167-194.
28. Tighe M, Roe MF. Does a teething child need serious illness excluding? *Arch Dis Child*. 2007;92(3):266-268.

## Childhood Fever

29. Van den Bruel A, Haj-Hassan T, Thompson M, Buntinx F, Mant D; European Research Network on Recognising Serious Infection Investigators. Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: a systematic review. *Lancet*. 2010;375(9717):834-845.
30. Finnell SM, Carroll AE, Downs SM; Subcommittee on Urinary Tract Infection. Technical report—diagnosis and management of an initial UTI in febrile infants and young children. *Pediatrics*. 2011;128(3):e749-e770.
31. Gorelick MH, Shaw KN. Screening tests for urinary tract infection in children: a meta-analysis. *Pediatrics*. 1999;104(5):e54.
32. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. *Pediatr Infect Dis J*. 2008;27(4):302-308.
33. Melendez E, Harper MB. Risk of serious bacterial infection in isolated and unsuspected neutropenia. *Acad Emerg Med*. 2010;17(2):163-167.
34. Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. *BMJ*. 2011;342:d3082.
35. Cincinnati Children's Hospital Medical Center. Evidence-based care guideline for fever of uncertain source in infants 60 days of age or less. October 27, 2010. <http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm>. Accessed May 30, 2012.
36. Ishimine P. The evolving approach to the young child who has fever and no obvious source. *Emerg Med Clin North Am*. 2007;25(4):1087-1115, vii.
37. Banks JB, Sullo EJ, Carter L. Clinical inquiries. What is the best way to evaluate and manage diarrhea in the febrile infant? *J Fam Pract*. 2004;53(12):996-999.
38. Andreola B, Bressan S, Callegaro S, Liverani A, Plebani M, Da Dalt L. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. *Pediatr Infect Dis J*. 2007;26(8):672-677.
39. Thayyil S, Shenoy M, Hamaluba M, Gupta A, Frater J, Verber IG. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? *Acta Paediatr*. 2005;94(2):155-158.
40. Olaciregui I, Hernández U, Muñoz JA, Empanaza JJ, Landa JJ. Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin. *Arch Dis Child*. 2009;94(7):501-505.
41. Manzano S, Bailey B, Girodias JB, Galetto-Lacour A, Cousineau J, Delvin E. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. *Am J Emerg Med*. 2010;28(6):647-653.
42. Mintegi S, Benito J, Astobiza E, Capapé S, Gómez B, Eguireun A. Well appearing young infants with fever without known source in the emergency department: are lumbar punctures always necessary? *Eur J Emerg Med*. 2010;17(3):167-169.
43. Baraff LJ. Management of infants and young children with fever without source. *Pediatr Ann*. 2008;37(10):673-679.
44. Bonsu BK, Harper MB. A low peripheral blood white blood cell count in infants younger than 90 days increases the odds of acute bacterial meningitis relative to bacteremia. *Acad Emerg Med*. 2004;11(12):1297-1301.
45. Bonsu BK, Chb M, Harper MB. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? *Ann Emerg Med*. 2003;42(2):216-225.
46. American College of Emergency Physicians Clinical Policies Committee; American College of Emergency Physicians Clinical Policies Subcommittee on Pediatric Fever. Clinical policy for children younger than three years presenting to the emergency department with fever. *Ann Emerg Med*. 2003;42(4):530-545.
47. American College of Radiology. ACR Appropriateness Criteria. Fever without source—child <http://www.acr.org/~media/ACR/Documents/AppCriteria/Diagnostic/FeverWithoutSourceChild.pdf>. Accessed October 12, 2012.
48. Hui C, Neto G, Tsertsvadze A, et al. Diagnosis and management of febrile infants (0-3 months). Evidence report/technology assessments, no. 205. Rockville, Md.: Agency for Healthcare Research and Quality; 2012.
49. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA*. 2003;289(2):203-209.
50. James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. *Antiviral Res*. 2009;83(3):207-213.
51. Kimberlin DW, Lin CY, Jacobs RF, et al.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics*. 2001;108(2):230-238.
52. Benito-Fernández J, Vázquez-Ronco MA, Morteruel-Aizkuren E, Mintegui-Raso S, Sánchez-Etxaniz J, Fernández-Landaluce A. Impact of rapid viral testing for influenza A and B viruses on management of febrile infants without signs of focal infection. *Pediatr Infect Dis J*. 2006;25(12):1153-1157.
53. Krief WI, Levine DA, Platt SL, et al.; Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Influenza virus infection and the risk of serious bacterial infections in young febrile infants. *Pediatrics*. 2009;124(1):30-39.
54. Levine DA, Platt SL, Dayan PS, et al.; Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. *Pediatrics*. 2004;113(6):1728-1734.
55. Doan Q, Enarson P, Kisson N, Klassen TP, Johnson DW. Rapid viral diagnosis for acute febrile respiratory illness in children in the emergency department. *Cochrane Database Syst Rev*. 2009;(4):CD006452.
56. Mintegi S, Garcia-Garcia JJ, Benito J, et al. Rapid influenza test in young febrile infants for the identification of low-risk patients. *Pediatr Infect Dis J*. 2009;28(11):1026-1028.
57. Ashkenazi-Hoffnung L, Livni G, Amir J, Bilavsky E. Serious bacterial infections in hospitalized febrile infants aged 90 days or younger: the traditional combination of ampicillin and gentamicin is still appropriate. *Scand J Infect Dis*. 2011;43(6-7):489-494.